David E. Wheadon - 30 Apr 2026 Form 4 Insider Report for Seaport Therapeutics, Inc. (SPTX)

Reporting relationship
Director
Issuer ticker
SPTX
Reported as of
30 Apr 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
04 May 2026, 18:10:27 UTC
Prior SEC filing
28 Jan 2026
Next SEC filing
14 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Lana Gladstein, Attorney-in-Fact

Key filing fact

David E. Wheadon filed Form 4 for Seaport Therapeutics, Inc. (SPTX) on 04 May 2026.

Key facts

  • This page summarizes David E. Wheadon's Form 4 filing for Seaport Therapeutics, Inc. (SPTX).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 04 May 2026, 18:10.

Change

  • Previous filing in this sequence was filed on 28 Jan 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001789507 Primary reporting owner

Wheadon David E.

Relationship
Director
Address
SEAPORT THERAPEUTICS, INC., 101 SEAPORT BLVD., FLOOR 12, BOSTON
Signature
/s/ Lana Gladstein, Attorney-in-Fact
Signature date
04 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SPTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+12,258
Change %
Price
$0.000000*
Shares after
12,258
Date
30 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
12,258
Exercise price
$18.00
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .